StockData
Acadia Pharmaceuticals Inc logo

Acadia Pharmaceuticals Inc (ACAD) stock

ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3027% below fair value
$18.32−0.35 (-1.87%)

Close on Nov 17, 2026Market cap $3.16BP/E 8.3Yield –

Acadia Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Acadia Pharmaceuticals's total assets was $1.74B at Jun 30, 2026. For fiscal 2025 it was $1.56B, up 31.7% from the year before. Over ten years it grew 21.6% a year on average. The highest annual figure on record is $1.56B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.56B+31.7%
FY2024Dec 31, 2024$1.19B+58.6%
FY2023Dec 31, 2023$748.96M+27.4%
FY2022Dec 31, 2022$587.81M-16.0%
FY2021Dec 31, 2021$700.12M-10.5%
FY2020Dec 31, 2020$782.62M-0.1%
FY2019Dec 31, 2019$783.18M+45.0%
FY2018Dec 31, 2018$540.20M+40.5%
FY2017Dec 31, 2017$384.51M-31.5%
FY2016Dec 31, 2016$561.15M+152.9%
FY2015Dec 31, 2015$221.90M-31.8%
FY2014Dec 31, 2014$325.46M+72.1%
FY2013Dec 31, 2013$189.12M+74.2%
FY2012Dec 31, 2012$108.59M+238.1%
FY2011Dec 31, 2011$32.11M-16.4%
FY2010Dec 31, 2010$38.39M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.74B+42.2%
Q1 FY2026Mar 31, 2026$1.61B+41.8%
Q4 FY2025Dec 31, 2025$1.56B+31.7%
Q3 FY2025Sep 30, 2025$1.33B+36.2%
Q2 FY2025Jun 30, 2025$1.23B+34.1%
Q1 FY2025Mar 31, 2025$1.13B+32.4%
Q4 FY2024Dec 31, 2024$1.19B+58.6%
Q3 FY2024Sep 30, 2024$976.87M+54.4%
Q2 FY2024Jun 30, 2024$914.10M+42.2%
Q1 FY2024Mar 31, 2024$855.10M+30.5%
Q4 FY2023Dec 31, 2023$748.96M+27.4%
Q3 FY2023Sep 30, 2023$632.54M+5.0%
Q2 FY2023Jun 30, 2023$642.77M+4.9%
Q1 FY2023Mar 31, 2023$655.31M+5.0%
Q4 FY2022Dec 31, 2022$587.81M-16.0%
Q3 FY2022Sep 30, 2022$602.49M-16.0%
Q2 FY2022Jun 30, 2022$612.77M-15.4%
Q1 FY2022Mar 31, 2022$624.25M-17.3%
Q4 FY2021Dec 31, 2021$700.12M-10.5%
Q3 FY2021Sep 30, 2021$717.67M-9.8%
Q2 FY2021Jun 30, 2021$724.43M-4.6%
Q1 FY2021Mar 31, 2021$755.17M+1.0%
Q4 FY2020Dec 31, 2020$782.62M-0.1%
Q3 FY2020Sep 30, 2020$795.66M+3.9%
Q2 FY2020Jun 30, 2020$759.65M+64.8%
Q1 FY2020Mar 31, 2020$747.45M+49.2%
Q4 FY2019Dec 31, 2019$783.18M+45.0%
Q3 FY2019Sep 30, 2019$765.59M+187.3%
Q2 FY2019Jun 30, 2019$460.88M+46.3%
Q1 FY2019Mar 31, 2019$501.11M+42.7%
Q4 FY2018Dec 31, 2018$540.20M+40.5%
Q3 FY2018Sep 30, 2018$266.46M-35.6%
Q2 FY2018Jun 30, 2018$314.96M-31.0%
Q1 FY2018Mar 31, 2018$351.04M-30.2%
Q4 FY2017Dec 31, 2017$384.51M-31.5%
Q3 FY2017Sep 30, 2017$413.71M-33.0%
Q2 FY2017Jun 30, 2017$456.32M–
Q1 FY2017Mar 31, 2017$503.01M–
Q4 FY2016Dec 31, 2016$561.15M–
Q3 FY2016Sep 30, 2016$617.38M–

More Acadia Pharmaceuticals figures

See a number that looks wrong?